Chun-ling Dai

1.7k total citations
19 papers, 1.4k citations indexed

About

Chun-ling Dai is a scholar working on Oncology, Molecular Biology and Surgery. According to data from OpenAlex, Chun-ling Dai has authored 19 papers receiving a total of 1.4k indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Oncology, 11 papers in Molecular Biology and 5 papers in Surgery. Recurrent topics in Chun-ling Dai's work include Drug Transport and Resistance Mechanisms (16 papers), Cancer therapeutics and mechanisms (8 papers) and Cholangiocarcinoma and Gallbladder Cancer Studies (5 papers). Chun-ling Dai is often cited by papers focused on Drug Transport and Resistance Mechanisms (16 papers), Cancer therapeutics and mechanisms (8 papers) and Cholangiocarcinoma and Gallbladder Cancer Studies (5 papers). Chun-ling Dai collaborates with scholars based in China, United States and Hong Kong. Chun-ling Dai's co-authors include Liwu Fu, Yong‐ju Liang, Zhe‐Sheng Chen, Amit K. Tiwari, Suresh V. Ambudkar, Chung‐Pu Wu, Liming Chen, Yan‐yan Yan, Kenneth K.W. To and Yan‐jun Mi and has published in prestigious journals such as PLoS ONE, Cancer Research and Biochemical Pharmacology.

In The Last Decade

Chun-ling Dai

19 papers receiving 1.4k citations

Peers

Chun-ling Dai
Yong‐ju Liang China
Elizabeth Hopper-Borge United States
Rishil J. Kathawala United States
Kamlesh Sodani United States
Chao‐Yun Cai China
J. H. Beijnen Netherlands
Alice A. Gibson United States
Zi‐Ning Lei United States
C.M. Kuiper Netherlands
Satyakam Singh United States
Yong‐ju Liang China
Chun-ling Dai
Citations per year, relative to Chun-ling Dai Chun-ling Dai (= 1×) peers Yong‐ju Liang

Countries citing papers authored by Chun-ling Dai

Since Specialization
Citations

This map shows the geographic impact of Chun-ling Dai's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Chun-ling Dai with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Chun-ling Dai more than expected).

Fields of papers citing papers by Chun-ling Dai

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Chun-ling Dai. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Chun-ling Dai. The network helps show where Chun-ling Dai may publish in the future.

Co-authorship network of co-authors of Chun-ling Dai

This figure shows the co-authorship network connecting the top 25 collaborators of Chun-ling Dai. A scholar is included among the top collaborators of Chun-ling Dai based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Chun-ling Dai. Chun-ling Dai is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

19 of 19 papers shown
1.
Dai, Chun-ling, Shaolin Ma, Fang Wang, et al.. (2015). Lapatinib promotes the incidence of hepatotoxicity by increasing chemotherapeutic agent accumulation in hepatocytes. Oncotarget. 6(19). 17738–17752. 15 indexed citations
2.
Deng, Wen, et al.. (2013). Tandutinib (MLN518) reverses multidrug resistance by inhibiting the efflux activity of the multidrug resistance protein 7 (ABCC10). Oncology Reports. 29(6). 2479–2485. 33 indexed citations
3.
Dai, Chun-ling, Shinobu Ohnuma, Yong‐ju Liang, et al.. (2013). Tandutinib (MLN518/CT53518) targeted to stem-like cells by inhibiting the function of ATP-binding cassette subfamily G member 2. European Journal of Pharmaceutical Sciences. 49(3). 441–450. 12 indexed citations
4.
Kuang, Yehong, Jay Pravin Patel, Kamlesh Sodani, et al.. (2012). OSI-930 analogues as novel reversal agents for ABCG2-mediated multidrug resistance. Biochemical Pharmacology. 84(6). 766–774. 18 indexed citations
5.
Tiwari, Amit K., Kamlesh Sodani, Chun-ling Dai, et al.. (2012). Nilotinib potentiates anticancer drug sensitivity in murine ABCB1-, ABCG2-, and ABCC10-multidrug resistance xenograft models. Cancer Letters. 328(2). 307–317. 101 indexed citations
6.
Wang, Fang, Yong‐ju Liang, Liming Chen, et al.. (2011). Prognostic value of the multidrug resistance transporter ABCG2 gene polymorphisms in Chinese patients with de novo acute leukaemia. European Journal of Cancer. 47(13). 1990–1999. 18 indexed citations
7.
Ding, Pei-Rong, Amit K. Tiwari, Shinobu Ohnuma, et al.. (2011). The Phosphodiesterase-5 Inhibitor Vardenafil Is a Potent Inhibitor of ABCB1/P-Glycoprotein Transporter. PLoS ONE. 6(4). e19329–e19329. 76 indexed citations
8.
Yan, Yan‐yan, Li-Sheng Zheng, Xu Zhang, et al.. (2011). Blockade of Her2/neu Binding to Hsp90 by Emodin Azide Methyl Anthraquinone Derivative Induces Proteasomal Degradation of Her2/neu. Molecular Pharmaceutics. 8(5). 1687–1697. 45 indexed citations
9.
Mi, Yan‐jun, Yong‐ju Liang, Hong-Yun Zhao, et al.. (2010). Apatinib (YN968D1) Reverses Multidrug Resistance by Inhibiting the Efflux Function of Multiple ATP-Binding Cassette Transporters. Cancer Research. 70(20). 7981–7991. 288 indexed citations
10.
11.
Abraham, Ioana, Sandeep Jain, Chung‐Pu Wu, et al.. (2010). Marine sponge-derived sipholane triterpenoids reverse P-glycoprotein (ABCB1)-mediated multidrug resistance in cancer cells. Biochemical Pharmacology. 80(10). 1497–1506. 46 indexed citations
12.
Dai, Chun-ling, Yong‐ju Liang, Xu Zhang, et al.. (2009). Sensitization of ABCB1 overexpressing cells to chemotherapeutic agents by FG020326 via binding to ABCB1 and inhibiting its function. Biochemical Pharmacology. 78(4). 355–364. 25 indexed citations
13.
Liang, Yong‐ju, Fang Wang, Liming Chen, et al.. (2009). Cediranib (recentin, AZD2171) reverses ABCB1- and ABCC1-mediated multidrug resistance by inhibition of their transport function. Cancer Chemotherapy and Pharmacology. 64(5). 961–969. 44 indexed citations
14.
Zhang, Jianye, Yong‐ju Liang, Yan‐yan Yan, et al.. (2009). Secalonic Acid D induced leukemia cell apoptosis and cell cycle arrest of G1 with involvement of GSK-3β/β-catenin/c-Myc pathway. Cell Cycle. 8(15). 2444–2450. 85 indexed citations
15.
Dai, Chun-ling, Yong‐ju Liang, Amit K. Tiwari, et al.. (2009). Sensitization of ABCG2-overexpressing cells to conventional chemotherapeutic agent by sunitinib was associated with inhibiting the function of ABCG2. Cancer Letters. 279(1). 74–83. 101 indexed citations
16.
Zheng, Li-Sheng, Fang Wang, Yuhong Li, et al.. (2009). Vandetanib (Zactima, ZD6474) Antagonizes ABCC1- and ABCG2-Mediated Multidrug Resistance by Inhibition of Their Transport Function. PLoS ONE. 4(4). e5172–e5172. 75 indexed citations
17.
Chen, Liming, et al.. (2009). Reversal of P-gp-mediated multidrug resistance by Bromotetrandrine in vivo is associated with enhanced accumulation of chemotherapeutical drug in tumor tissue.. PubMed. 29(11). 4597–604. 21 indexed citations
18.
Dai, Chun-ling, Amit K. Tiwari, Chung‐Pu Wu, et al.. (2008). Lapatinib (Tykerb, GW572016) Reverses Multidrug Resistance in Cancer Cells by Inhibiting the Activity of ATP-Binding Cassette Subfamily B Member 1 and G Member 2. Cancer Research. 68(19). 7905–7914. 333 indexed citations
19.
Dai, Chun-ling, Xu Zhang, Yong‐ju Liang, et al.. (2007). Tetrandrine achieved plasma concentrations capable of reversing MDR in vitro and had no apparent effect on doxorubicin pharmacokinetics in mice. Cancer Chemotherapy and Pharmacology. 60(5). 741–750. 52 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Yong‐ju Liang Breakdown of academic impact, for papers by Elizabeth Hopper-Borge Breakdown of academic impact, for papers by Rishil J. Kathawala Breakdown of academic impact, for papers by Kamlesh Sodani Breakdown of academic impact, for papers by Chao‐Yun Cai Breakdown of academic impact, for papers by J. H. Beijnen Breakdown of academic impact, for papers by Alice A. Gibson Breakdown of academic impact, for papers by Zi‐Ning Lei Breakdown of academic impact, for papers by C.M. Kuiper Breakdown of academic impact, for papers by Satyakam Singh
Rankless by CCL
2026